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comparing two groups with high heterogeneity in baseline char-
acteristics.
Furthermore, to avoid a basic misunderstanding of the objective
of our study, one specific point needs to be emphasized. The study
was not designed to address the question of whether one beta-
blocker is more effective than another, but rather (as clearly
stated in our article) to evaluate whether carvedilol may provide
additional benefits in a select subgroup of patients with dilated
cardiomyopathy who were treated long term with metoprolol, as
well as poor responders to metoprolol. Therefore, the lack of
further benefits in patients randomized to continue taking meto-
prolol was, in some way, expected. However, from this evidence,
we have not argued (or stated) that metoprolol is ineffective or less
effective than carvedilol; rather, we have suggested that carvedilol
treatment may be beneficial in patients showing unsatisfactory
clinical responses to metoprolol treatment.
Finally, we agree with the comments made by Drs. Fauchier
and Giraudeau regarding the U.S. Carvedilol Study (2) and the
MERIT-HF trial (3), even though it cannot be denied that the
data from the U.S. program, at least, imply a beneficial effect of
carvedilol on sudden death. In any case, whatever the opinion on
this issue, the truth is that the comparative efficacy of carvedilol
and metoprolol in preventing sudden death will remain an open
question until the conclusion of the ongoing COMET trial.
We thank Drs Fauchier and Giraudeau for having brought their
pertinent criticisms to our attention.
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Pharmacologic Stress Echocardiography:
Can We Forget “State-of-the-Art” Protocols?
In a recent issue of the Journal, Fragasso et al. (1) reported on the
comparison of different stress imaging modalities for the detection
of coronary artery disease in hypertensive patients. Their final
conclusion was that stress echocardiography appears to be the most
valuable tool for predicting significant coronary artery disease, and
that among pharmacologic stressors, dobutamine stress echocardi-
ography should be the first choice. In my opinion, this statement
should be read with caution. First of all, the authors applied
protocols of stress testing that do not represent the accepted
“state-of-the-art” modalities of pharmacologic echocardiography.
In case of a negative stress test response, atropine was not used
either during dobutamine or dipyridamole echocardiography. Al-
though they mentioned that atropine coadministration improves
the diagnostic power of both tests, they explicitly stated that the
accuracy of dobutamine stress remains higher. I must disagree with
this statement. It is well known from a large-scale, multicenter
study, that in a group of patients taken off beta-blockers (such as
those studied by Fragasso et al.), atropine coadministration dra-
matically increases the sensitivity of dipyridamole testing, whereas
it only mildly affects the sensitivity of dobutamine echocardiogra-
phy (2). Atropine coadministration with dobutamine markedly
increases the test sensitivity in a group taking beta-blockers (3).
Moreover, in a meta-analysis of 12 reports comparing head-to-
head dipyridamole and dobutamine echocardiography, there was
no significant difference in the diagnostic accuracy of both tests.
Dobutamine was more sensitive in patients with one-vessel dis-
ease, but this advantage disappeared in patients with multivessel
disease. The specificity of dipyridamole was consistently higher,
and the accuracy of the two tests was similar (4). The result of the
meta-analysis is perfectly in agreement with the data of Fragasso et
al., showing that the accuracy of the two tests is similar, with a
higher sensitivity of dobutamine in single-vessel disease and a
higher specificity of dipyridamole in patients with normal coronary
arteries. Interestingly, Astarita et al. (5) have recently studied
dipyridamole/atropine echocardiography and perfusion scintigra-
phy in hypertensive patients with a positive exercise electrocardi-
ography test. Using the same selection criteria of Fragasso et al.,
they also showed a similar sensitivity and higher specificity of
Table 1. Coefficient Estimates of Our Statistical Model Adjusted for Baseline Values and Confounding Factors
Variable Delta Intercept Baseline
Mild
Hypertension
(yes vs. no)
Duration of
Symptoms
(months)
Amiodarone
Treatment
(yes vs. no)
Treatment
(metoprolol vs. carvedilol)
VEB/h 6 mo 38.93 20.33* 237.93 20.27 225.89 28.67
VEB/h 12 mo 53.03 20.32 2119.38* 20.39 239.10 101.26*
Couplets/h 6 mo 20.52 0.046 0.23 0.003 20.21 0.83
Couplets/h 12 mo 20.337 20.118 20.887 0.004 21.121 1.818*
NSVT/h 6 mo 20.02 20.33* 20.005 0.0004* 20.02 0.02
NSVT/h 12 mo 20.03 20.10 20.03 0.0005* 20.01 0.03
*p , 0.05.
NSVT 5 nonsustained ventricular tachycardia; VEB 5 ventricular ectopic beats.
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dipyridamole stress echocardiography versus perfusion scintigra-
phy. In contrast to Fragasso et al., Astarita et al. used a “state-of-
the-art” atropine protocol, and they in fact observed that dipyrid-
amole sensitivity was raised to 88%. Stress echocardiography
protocols have evolved rapidly in recent years. When the diagnosis
is the target, atropine coadministration should be used. When
prognostic stratification is the reason for testing, a high dose
without atropine, even in hypertensive patients (6), provides
excellent stratification (7).
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REPLY
We are grateful to Dr. Varga for his comments on our report (1),
because his letter gives us the opportunity to further clarify our
opinion. Like others (2), in the past, we have used dipyridamole for
the diagnosis of coronary artery disease, but we (3) have been unable
to reproduce the diagnostic accuracy reported by some groups.
Interestingly enough, the near totality of these data comes from a
single institution. In our study, we decided not to use atropine to
assess the intrinsic strength of the individual stressors. The sensitivi-
ties and specificities for perfusion scintigraphy, dipyridamole and
dobutamine echocardiography were 98% and 36%, 61% and 91%,
88% and 80% respectively. As a consequence, accuracy, which takes in
account both sensitivity and specificity, was not significantly different
between the three tests, although dobutamine appeared to perform
better (84%) than dipyridamole (74%) and scintigraphy (71%). Fur-
thermore, in patients with one-vessel disease, the performance of
dipyridamole was very poor, with a sensitivity of 31%. We do not
think that the addition of atropine could have increased this figure to
an acceptable level, especially if we take into account that, in this
subgroup, the sensitivities of dobutamine and scintigraphy were 85%
and 95%, respectively. Indeed, we believe that such differences are
enough to justify our statement that dobutamine echocardiography (as
well as rest/stress myocardial perfusion scintigraphy) are better than
dipyridamole echocardiography in these patients. We cannot afford
the risk of missing so many patients with coronary artery disease in
such a high-risk group. In addition, this statement is also justified by
pathophysiologic considerations. Dobutamine increases oxygen de-
mand by increasing contractility, heart rate and systolic blood pres-
sure. These features make dobutamine an ideal stressor in hyperten-
sion. In contrast, dipyridamole produces coronary vasodilation, with
little “myocardial stress,” as defined by changes in the rate–pressure
product and a lesser likelihood of causing myocardial ischemia. This
is why dipyridamole yields high sensitivities when used with scintig-
raphy, where perfusion abnormalities are thought to represent areas of
altered blood flow rather than areas of ischemia; however, this is also
why its sensitivity is low when used with echocardiography.
Surely, the addition of atropine improves sensitivity, but it also
leaves misdiagnosed a large proportion of patients with single-
vessel disease. Furthermore, although dipyridamole is considered a
safe test, most patients experience considerable side effects. Ami-
nophylline is administered at the end of the test, and, when
atropine has also been given, sustained sinus tachycardia usually
ensues, causing discomfort and making the duration of the test as
long as dobutamine testing. On the basis of these considerations,
we think that dobutamine provides the best performance for the
diagnosis of coronary artery disease in hypertensive patients (and
beyond). Our feeling (allowed in a letter!) is that most cardiologists
around the world share the same opinion.
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Overdosing With Prostacyclin
in Primary Pulmonary Hypertension
Rich and McLaughlin (1) reported excessively high rest cardiac
outputs in 12 of 55 patients with primary pulmonary hypertension
(PPH) treated with intravenous prostacyclin, all of whom had
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